The CEO's super-voting preferred shares ensure Proposal 3 will pass regardless of common shareholder opposition. Monitor for the actual number of shares issued under the expanded plan and any subsequent dilutive offerings.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 16 $2.60entry
- T+1 · 5d ago −2.31%α −1.29% · $2.54
- T+4 · todayOpen
- T+5 · in 23h Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Sunshine Biopharma filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting, reminding shareholders to vote on three proposals: electing five directors, ratifying the auditor, and approving a massive 2,050x increase in the 2023 Equity Incentive Plan share reserve from 3,415 to 7,000,000 shares. The CEO holds 130,000 Series B Preferred shares with 1,000 votes each, giving him effective control over all voting matters, and the company has sustained net losses of $5.98M in 2025 with zero total shareholder return over three years.
Key Financial Metrics
Key Facts
- Meeting date: December 29, 2026; record date not stated
- Proposal 3 seeks to increase the 2023 Equity Incentive Plan share reserve from 3,415 to 7,000,000 shares (2,050x increase)
- CEO holds 130,000 Series B Preferred shares with 1,000 votes each, giving effective control over all voting matters
- Company sustained net losses of $5.98M in 2025, $5.13M in 2024, and $4.51M in 2023
- Zero total shareholder return over three years
- Market cap is $2M; the proposed 7M share reserve represents massive potential dilution relative to current market cap
Financial Impact
Proposed 2,050x increase in equity plan share reserve from 3,415 to 7,000,000 shares; company has $2M market cap and sustained $5.98M net loss in 2025
Risk Factors
- Massive dilution from 7M share reserve relative to $2M market cap
- CEO control via super-voting preferred shares eliminates shareholder check on dilution
- Sustained net losses with no path to profitability disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001683168-26-008699 |
| Document: 0001683168-26-008699-index-headers.html | 0001683168-26-008699 |
| Document: 0001683168-26-008699-index.html | 0001683168-26-008699 |
| Document: 0001683168-26-008699.txt | 0001683168-26-008699 |
Track record
15 reports on SBFM
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +69.19% at T+20 after the Oct 8, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 18, 20263d ago S-1 Bearish 6/10 Entry $2.35 Now $2.23 +5.11% settles Nov 27
- Nov 13, 20268d ago DEFA14A Bearish 5/10 Viewing Entry $2.60 Now $2.23 +14.23% settles Nov 23
- Nov 12, 20269d ago DEF 14A Bearish 5/10 Entry $2.70 to $2.23 Now $2.23 +17.41% ▲ +17.41% +8.85% vs SPY
- Nov 10, 202611d ago SC 13G/A Neutral 2/10 Entry $2.75 to $2.41 Now $2.23 −18.91% ▼ −12.36% −8.47% vs SPY
- Oct 14, 20265w ago SC 13G Neutral 3/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
- Oct 13, 20265w ago SC 13G Neutral 4/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
- Oct 9, 20266w ago 8-K Bearish 6/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
- Oct 9, 20266w ago 424B4 Bearish 7/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
- Oct 8, 20266w ago EFFECT Bearish 6/10 Entry $8.60 to $4.60 Now $2.23 +74.07% ▲ +46.51% +46.24% vs SPY
- Oct 5, 20266w ago SC 13G/A Bearish 5/10 Entry $0.3979 to $0.2363 Now $2.23 −460.44% ▲ +40.61% +40.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers